EUCTR2015-000373-13-DE进行中（未招募）不适用
Phase 2, multicenter, randomized, double-blind, placebo-controlled, four-period cross-over, dose-range finding study to evaluate the safety, tolerability and efficacy of Eltoprazine in the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A patient will be invited to participate if he/she meets the following inclusion criteria:
- •1. willing and able to provide written informed consent
- •2. age 30 to 85 years, inclusive
- •3. outpatient with idiopathic PD according to the UK Parkinson’s Disease Society Brain Bank Clinical Diagnosis Criteria (UKPDSBBCDC)
- •4. on a PD treatment regimen with a stable dose of anti-Parkinsonian medication for at least four weeks before the Screening Visit (levodopa, DDIs, COMT inhibitors, dopamine agonists and MAO-B inhibitors)
- •5. treated with a daily levodopa dose (immediate or extended release formulation) more than 300 mg per day divided into at least three doses
- •6. treated with levodopa for at least three years prior to study entry
- •7. has been experiencing levodopa induced peak-dose dyskinesia for at least three months prior to study entry
- •8. experiences disabling dyskinesia (Screening Visit MDS-UPDRS Part IV question 4.2 score =2)
- •9. has dyskinesia for, on average, >25% of the waking day based on patient reported dyskinesia (tablet diaries) during the second week of the screening period
- •10. has the ability to communicate adequately with the study staff and to comply with the requirements of he entire study, with the help of a caregiver if applicable
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •A patient will be excluded from study participation if he/she meets any of the following
- •1. inability to use the Kinesia 360 system (tablet or motion sensors) correctly,
- •diaries not completed in a timely manner or two or more hours’ worth of missing waking day entries” or times PD-LID medication taken missing
- •2. surgical treatment for PD (e.g. DBS), within the last six months or planned during the study
- •3. unstable co-existing psychiatric disease including psychosis, depression or
- •cognitive impairment that, according to the Investigator, could interfere with the conduct of the study
- •4. has an MMSE score of <24
- •5. has a known clinically significant allergy or known hypersensitivity to drugs that, in the opinion of the Investigator, may affect the patient’s safety
- •6. has moderate or severe renal or severe hepatic impairment and/or has clinically significant abnormal laboratory parameters at screening, in particular, liver or renal function tests greater than 1.5 times the upper limit of normal (ULN) or any other clinically significant biochemical or hematological abnormality as determined by the Investigator
- •7. treatment with selective serotonin re-uptake inhibitors (SSRI) or any combined serotonin-norepinephrine re-uptake inhibitors (SNRI) such as tryptizol, citalopram, escitalopram, sertraline, mianserin, mirtazapin, paroxetin, venlafaxine and St John’s Wort, within four weeks prior to the Screening Visit.
- •8. other medication with the potential for drug-interactions (MAO-A inhibitors,
- •apomorphine, aripiprazol, carbamazepine, clozapine, phenytoin, tramadol,
- •quetiapine, varfaine, valproic acid). Patients taking amantadine may be included if the amantadine is being used according to its indication for the treatment of PD and not specifically for dyskinesia and the dose remains stable throughout the trial. Patients taking amantadine will comprise no more than 25% of the study population
- •9. No clinically significant 12-lead ECG abnormalities and with a QTc value of
- •<450 ms for men and <460 ms for women.
- •10. has a current history of a clinically significant and uncontrolled medical condition that may affect the safety of the patient or preclude adequate participation in the study, including but not limited to orthostatic hypotension causing syncope, uncontrolled ischemic heart disease, uncontrolled brady- or tachy-arrhythmias, chronic obstructive pulmonary disease, diabetes and epilepsy
- •11. is pregnant or breast-feeding. Female patients who are of child-bearing potential must be using adequate contraceptive methods (e.g. oral contraceptive, doublebarrier method, intra-uterine device, intra-muscular hormonal contraceptive), and have a negative pregnancy test at Screening
- •12. has received any other investigational medicinal product within 30 days of Screening
- •13. is a member of, or relative of, the study site staff and/or employees or consultants of Amarantus BioScience
研究者
相似试验
进行中（未招募）
不适用
Safety and efficacy study of TRO40303 for reduction of reperfusion injury in patients undergoing Percutaneous Coronary Intervention for acute myocardial infarctioEUCTR2010-024616-33-SETROPHOS SA
进行中（未招募）
1 期
Safety and efficacy study of TRO40303 for reduction of reperfusion injury in patients undergoing Percutaneous Coronary Intervention for acute myocardial infarctioTreatment for cardiac reperfusion injury in patients undergoing PCI( Percutaneous coronary intervention) to treat an AMI (Acute Myocardial Infarction) and to assess safety as well as the ability of TRO40303 to reduce infarct size using biomarkers and MRI (Magnetic Resonance Imaging)MedDRA version: 14.1Level: LLTClassification code 10000930Term: Acute myocardial infarction, unspecified site, initial episode of careSystem Organ Class: 10007541 - Cardiac disordersEUCTR2010-024616-33-DKTROPHOS SA180
进行中（未招募）
不适用
Phase II, multicenter, randomized, double-blind, intraindividually placebo controlled clinical trial, to evaluate efficacy and safety of P144 topical administration for skin fibrosis in patients with systemic sclerosis.Fázis II, multicentrikus, randomizált, kettos vak, egyénenként placebóval kontrollált klinikai vizsgálat, különbözo koncentrációjú topikus P144 hatékonyságának és biztonságosságának megállapítása szisztémás sclerosis-ban szenvedo páciensek bor fibrózisának kezelésében.SKIN FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSISMedDRA version: 9.1Level: LLTClassification code 10039710Term: SclerodermaEUCTR2007-002015-38-HUISDI98
进行中（未招募）
不适用
Phase II, multicenter, randomized, double-blind, intraindividually placebo controlled clinical trial, to evaluate efficacy and safety of P144 topical administration for skin fibrosis in patients with systemic sclerosis. - NDSkin Fibrosis in patients with systemic sclerosisMedDRA version: 12.0Level: LLTClassification code 10039710Term: SclerodermaEUCTR2007-002015-38-ITISDIN S.A.98
进行中（未招募）
不适用
Phase II, multicenter, randomised, double-blind, placebo-controlled, parallel group, dose-ranging study to determine the effect on MRI lesions and safety of RO0506997 in Relapsing Multiple SclerosisRelapsing Multiple SclerosisEUCTR2004-004519-43-GBF. Hoffmann-La Roche Ltd200